news Targovax appoints of Øystein Soug as CEO 4 November 2016 | By Niamh Louise Marriott, Digital Content Producer Øystein Soug is the former CFO of Algeta, a Norwegian oncology biotech company which was sold to Bayer for USD 2.9 billion in 2014...
news Bayer and X-Chem expand drug discovery collaboration 12 July 2016 | By Victoria White, Digital Content Producer In a deal worth up to $528 million, Bayer and X-Chem are to collaborate to discovery therapies across multiple therapeutic areas and target classes...
article Leaving EU could be a setback for Life Sciences in the UK 8 June 2016 | By Dr Alexander Moscho, Bayer UK & Ireland CEO In this opinion piece, Dr Alexander Moscho, Bayer UK & Ireland CEO, says a vote to leave the EU will deter investment and make it harder for patients to access new medicines...
news Collaboration to develop new treatments for tuberculosis 8 March 2016 | By Victoria White Scientists at the Universities of Dundee and Cape Town are teaming up with Bayer to develop critically needed new treatments for tuberculosis...
news Bayer and CRISPR Therapeutics join forces for breakthrough therapies 21 December 2015 | By Victoria White Bayer and CRISPR Therapeutics are to form the joint venture to discover, develop and commercialise new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease...
news International consortium CANCER-ID to develop novel biomarker technologies in cancer 23 April 2015 | By Victoria White Bayer and UKE are the main coordinators of a new international consortium, CANCER-ID, to develop novel blood-based biomarker technologies in cancer...
news Broad Institute and Bayer HealthCare expand collaboration to help create new cardiovascular therapies 13 April 2015 | By Victoria White Bayer HealthCare has expanded its collaboration with the Broad Institute to include cardiovascular genomics and drug discovery...
article Molecular Target Validation in preclinical drug discovery 2 May 2014 | By Isabella Gashaw (Bayer HealthCare Pharmaceuticals), Karl Ziegelbauer (Bayer HealthCare Pharmaceuticals), Khusru Asadullah (Bayer HealthCare Pharmaceuticals), Martin Bechem (Bayer HealthCare Pharmaceuticals) Preclinical drug target validation has the aim to increase confidence in a particular drug target. The process proves the initial hypothesis that a particular molecular target is key or even causative for pathogenic or symptomatic mechanisms in a disease. Several success factors seem to be of particular importance for the…
news Bayer and Onyx report Phase 3 study results of NEXAVAR® (sorafenib) as adjuvant treatment for patients with liver cancer 12 March 2014 | By Amgen Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., announced that a Phase 3 trial evaluating the investigational use of NEXAVAR® (sorafenib) tablets as an adjuvant treatment for patients with hepatocellular carcinoma...